Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Novagali Pharma Recognized for its Innovation in Ophthalmic Therapies Improving the Administration, Bioavailability and Safety of Treatments - Frost & Sullivan recognizes Novagali Pharma with the 2009 North American Frost & Sullivan Award for Industry Innovation & Advancement of the Year, for its two proprietary emulsion technology platforms, Novasorb and Eyeject
Novagali Pharma Recognized for its Innovation in Ophthalmic Therapies Improving the Administration, Bioavailability and Safety of Treatments

 

PRZOOM - /newswire/ - Mountain View, CA, United States, 2009/03/19 - Frost & Sullivan recognizes Novagali Pharma with the 2009 North American Frost & Sullivan Award for Industry Innovation & Advancement of the Year, for its two proprietary emulsion technology platforms, Novasorb and Eyeject.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the ocular drug delivery market, Frost & Sullivan recognizes Novagali Pharma with the 2009 North American Frost & Sullivan Award for Industry Innovation & Advancement of the Year, for its two proprietary emulsion technology platforms, Novasorb and Eyeject.

It is estimated that as little as five percent of a topically applied drug ever reaches the intraocular tissues due to drug loss as the result of tearing, lacrimal fluid-eye barriers, and blood-ocular barriers. These beneficial natural defenses, which protect the eyes and block foreign substances, also greatly limit the usefulness of topical treatments for treating them when distressed or diseased. This is true, in particular, for diseases of the posterior of the eye.

"Novagali recognizes this as an opportunity and is working diligently with its proprietary emulsion technologies to overcome both pharmacological and drug delivery challenges in the eye," says Frost & Sullivan Research Analyst Misty Hughes. "With research truly encompassing all segments of the eye, Novagali's Novasorb is optimized to treat a number of diseases by improving drug delivery to the front of the eye, while the minimally-invasive Eyeject intra-ocular platform offers improvements over existing implant technology in treating challenging diseases of the eye's posterior."

Novasorb is a cationic emulsion technology platform being investigated to treat dry eye, glaucoma, allergies, and anterior uveitis. As the effective treatment of surface ocular conditions is often limited by dispersion and lubrication, Novasorb technology increases the absorption and efficacy of drugs in ocular tissues through electrostatic attraction between the positive charge of the therapeutic emulsion and the eye's negatively charged mucous, cornea, and conjunctiva. Furthermore, the electrostatic attraction and colloidal properties that increase therapeutic residence time on the eye's anterior, also benefit the eye's posterior. Increased contact and penetration into the cornea and conjunctiva allows for more of the drug to diffuse to the anterior segment as well.

Compared to conventional eye drops and anionic emulsions, Novasorb formulations exhibit a four-fold higher spreading coefficient allowing for increased wettability of the eye's surface while also protecting against mechanical damage that occurs from blinking. This increase in residence time on the surface of the eye is key to achieving therapeutic drug levels when treating ocular conditions. It also means the patient will require fewer instillations, which will undoubtedly decrease side effects and increase patient compliance.

Novagali has further expanded upon its novel emulsion technology platform to also treat serious diseases of the back of the eye. Eyeject is an intra-ocular delivery platform that offers a minimally-invasive alternative to ocular implants for treating disease in the eye's posterior. This injectable emulsion provides a prolonged, controlled release of medication at the retina and choroid, yet can easily be administered in a non-surgical setting. Safe and effective, Eyeject is an organic, solvent- and preservative-free emulsion that includes only ophthalmologically biocompatible excipients. Novagali is investigating Eyeject's use in treating a number of posterior ophthalmic diseases, including macular edema and diabetic retinopathy.

Novagali's broad research portfolio includes seven compounds that utilize Novasorb or Eyeject technology to treat not only common eye conditions, but orphan diseases as well. Commercialized for sale in France in April 2008 and an expected U.S. launch, Cationorm®, an over-the-counter (OTC) dry eye treatment developed on the basis of Novasorb technology, is the company's first product from its pipeline to reach the market. The company's other lead drug candidates in development in the U.S. include Cyclokat (NOVA22007), a Novasorb-based therapy in phase III trials for moderate-to-severe dry eye, and Cortiject (NOVA63035), a corticosteroid formulated with Eyeject technology that is in phase I trials for diabetic macular edema.

"The development of new products that operate through novel mechanisms of action is vital to future advancements in ocular drug delivery," stresses Hughes. "Through focused research into novel treatment modalities in ophthalmics, Novagali Pharma's proprietary technology platforms are set to greatly benefit both patients and healthcare practitioners in the near future."

In recognition of Novagali's dedication and pioneering research in this field Frost & Sullivan is proud to present it with the 2009 North American Industry Innovation and Advancement of the Year Award in ocular drug delivery.

Each year, Frost & Sullivan presents this award to the company that has proven to be a leader in the industry and that, through its pioneering technology, sound business strategy, and research efforts, has been successful in moving the state of the industry forward. Its excellence in the field has extended beyond its technical advancements and encompasses a comprehensive view of market participants, resulting in an ongoing improvement in the industry, more comprehensive participation in the industry and for its contributions to the advancement of the market.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Novagali Pharma

Novagali Pharma (novagali.com) is an ophthalmic pharmaceutical company that develops and commercializes innovative products. Thanks to its proprietary technology platforms Novasorb® and Eyeject®, the company has developed innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia®, for treatment of vernal keratoconjunctivitis, Cyclokat®, for the treatment of moderate-to-severe dry eye syndrome and Cortiject® for the treatment of diabetic retinopathies. Cationorm®, indicated for dry eye symptoms is commercialized in France since April 2008. Founded in 2000, Novagali Pharma is based in the Génopôle biocluster in Evry (France).

About Frost & Sullivan

Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Novagali Pharma Recognized for its Innovation in Ophthalmic Therapies Improving the Administration, Bioavailability and Safety of Treatments

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Jake Wengroff 
210.247.3806 jake.wengroff[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Triggr & Bloom







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today